prognosistargeted therapyTo the Editors: On the basis of human epidermal growth factor receptor 2 ( HER-2 ) status, patients with breast cancer are classified as having HER-2 -negative or HER-2 -positive disease. Prognosis of HER-2 -positive, as compared to HER-2 -negative, disease is ...
Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response Fara Brasó-Maristany, Juan Manuel Ferrero-Cafiero, Claudette Falato, Olga Martínez-Sáez, Juan Miguel Cejalvo, Mireia...
孕激素受体对HER-2阴性乳腺癌患者转移和预后的影响(Influence of progesterone receptor on metastasis and prognosis in breast cancer patients with negative HER-2) 内容亮点 探讨转移性乳腺癌不同单一阳性激素受体亚型[雌激素受体(ER)...
HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma......
Keyword:Her-2 negative breast cancer;Neoadjuvant chemotherapy;Efficacy assessment; Untoward effect ;Prognostic evaluation 0 引言 当前,随着社会各方面飞速发展进步,快节奏的生活,工作状态使得身体及心理负担加重,伴随整个社会人口老龄化的持续加剧,近几年来,我国癌症负担明显加重,癌症的发病率和死亡率逐年上升[1] 。
本文围绕HER-2阳性乳腺癌患者的抗HER-2靶向药物及个体化治疗治疗做一综述。Abstract:Withthedeepeningofmolecularbiologyresearch,breakthroughshavebeenmadeintheresearchandclinicalapplicationoftumortargetedtherapy.TheHER-2genehasimportantguidingvalueinthediagnosis,treatmentandevaluationofprognosisofbreastcancer.Thisarticle...
HER-2-positive cancers tend to be high grade, aggressive and carry a poor prognosis; however, they respond well to trastuzumab, an anti-HER-2 monoclonal antibody. Conversely, triple-negative carcinomas are extremely aggressive and currently do not respond to any hormonal or antibody-based ...
2023年8月, Frontiers in Oncology杂志发表了一项研究,题为《HER-2 ultra-low breast cancer: exploring the clinicopathological features and prognosis in a retrospective study》,为我们提供了关于HER-2超低表达乳腺癌的深入分析。 研...
Benefits were also seen for the combination of trastuzumab with lapatinib or pertuzumab, suggesting that dual blockage of the HER-2 will probably emerge as the new standard. Triple-negative phenotype is also predictive of high pCR to NT, but the prognosis of patients whose tumours do not ...
【Keywords】 Human epidermal growth factor receptor 2 mutation; Breast cancer; Drug resistance; Target therapy 人表皮生长因子受体2(human epidermal growth factor receptor 2,HER-2)基因扩增阳性乳腺癌占所 有乳腺癌的20% ～ 30%,与肿瘤的高侵袭性,高复 发风险,进展快速及不良预后相关[1-2].以曲妥珠单 ...